Press release
Celiac Disease Market is projected to reach USD 10.14 billion by 2034
Celiac Disease
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71310
Celiac disease is an autoimmune disorder triggered by gluten ingestion, leading to chronic inflammation and damage of the small intestinal mucosa. It affects genetically predisposed individuals carrying HLA-DQ2 or HLA-DQ8 alleles. Untreated, it can result in nutrient malabsorption, anemia, osteoporosis, infertility, neurological symptoms, and increased risks of lymphoma.
While strict gluten-free diet adherence remains the primary treatment, pharmaceutical interventions-including enzyme therapies, tight junction modulators, immune-targeting biologics, and gluten neutralizers-are progressing through clinical trials, indicating a major shift in future therapeutic strategies.
Key Market Highlights
• 2024 Market Size: USD 4.62 billion
• 2034 Forecast: USD 10.14 billion
• CAGR (2025-2034): 8.1%
• Largest Segment: Gluten-free foods & beverages
• Fastest-Growing Segment: Novel therapeutics in clinical development
Epidemiology & Patient Insights
1. Prevalence
• Affects 1-2% of the global population, though many cases remain undiagnosed.
• Prevalence is rising due to improved serological screening and awareness.
2. High-Risk Groups
• Individuals with Type 1 diabetes
• Autoimmune thyroid disease
• First-degree relatives of celiac patients
• Down syndrome
• Selective IgA deficiency
3. Clinical Manifestations
• Gastrointestinal symptoms: diarrhea, bloating, weight loss
• Extraintestinal symptoms: dermatitis herpetiformis, anemia, fatigue, neuropathy
• Long-term complications include:
o Osteoporosis
o Infertility
o Small bowel lymphoma
4. Diagnostic Advances
Improved detection through:
• Anti-tTG IgA testing
• EMA antibody testing
• Deamidated gliadin peptide (DGP) assays
• Genetic HLA testing
• High-resolution endoscopy & biopsy
Market Growth Drivers
1. Growing Adoption of Gluten-Free Diets
GF foods have become mainstream, driving a multi-billion-dollar segment within the celiac disease market.
2. Increasing Disease Awareness
Campaigns by patient advocacy groups and healthcare organizations support early diagnosis.
3. Advances in Diagnostics
Highly accurate serological and genetic tests expand screening efficiency.
4. Pipeline Therapies Entering Late-Stage Trials
Key mechanisms under development include:
• Enzymatic breakdown of gluten
• Tight-junction stabilization
• Immune tolerance induction
• Autologous immunotherapy
5. Rise of Comorbid Autoimmune Conditions
More screenings in Type 1 diabetes and thyroid disorders increase detection rates.
Market Restraints
• Lack of approved curative or disease-modifying drugs
• Complexity and high cost of maintaining a GF diet
• Cross-contamination risks in processed foods
• Inconsistent diagnosis in low-resource settings
• Limited adherence to long-term dietary restrictions
Market Opportunities
1. First-in-Class Therapeutics
A major unmet need exists for medications that prevent gluten-triggered immune responses.
2. Personalized Nutrition & Digital Tools
AI-driven meal planning apps and genetic profiling support individualized disease management.
3. Expansion of GF Food Manufacturing
Growing consumer demand is fueling investments in GF product innovation and certification.
4. At-Home Screening Kits
Home-based antibody testing solutions are gaining traction.
5. Blockchain in Gluten Supply Chain Tracking
Ensures purity and safety of GF-labeled foods.
Segmentation Overview
By Treatment
• Gluten-free diet (primary treatment)
• Enzyme therapy (pipeline)
• Tight junction modulators
• Immune tolerance therapies
• Symptom-targeting medications
By Diagnostic Method
• Serological testing
• Genetic testing
• Endoscopy & biopsy
• Point-of-care home testing
By Product Type
• Gluten-free foods
• Gluten-free beverages
• Gluten-free supplements
By Distribution Channel
• Retail stores
• Pharmacies
• Online stores
• Specialty health shops
By End User
• Hospitals
• Gastroenterology clinics
• Diagnostic laboratories
• Home users
Explore Full Report here: https://exactitudeconsultancy.com/reports/71310/celiac-disease-market
Regional Insights
North America - Largest Market
Advanced diagnostics, high consumer interest in gluten-free products, and expanding research activity.
Europe - Strong Clinical Adoption
High awareness and reimbursement for diagnostics; robust GF food manufacturing industry.
Asia Pacific - Fastest Growth
Increasing diagnosis rates, urban lifestyle shifts, rising gluten sensitivity awareness.
Latin America - Moderate Growth
Growing GF food industry and increasing screenings.
Middle East & Africa - Emerging
Limited diagnosis but improving access to gastroenterology services.
Competitive Landscape
Key companies in the Celiac Disease Market include:
• BioLineRx
• Takeda Pharmaceuticals
• ImmunogenX
• Cour Pharmaceuticals
• Activa Therapeutics
• Alba Therapeutics
• Dr. Schär
• General Mills
• Kellogg's
• Kraft Heinz
These players focus on:
• Gluten-free food innovation
• Enzyme therapies
• Immune-modulating treatments
• Next-generation diagnostics
Recent Market Developments
• Late-stage clinical trials for gluten-targeting enzyme therapies
• Significant growth in certified GF product lines globally
• Advances in immune tolerance treatments
• Launch of at-home celiac disease testing platforms
• Improved labeling regulations for gluten-containing foods
Future Outlook (2025-2034)
The Celiac Disease Market will expand significantly as:
• Novel therapeutics advance toward approval
• GF diet market continues rapid global growth
• Diagnostic accuracy improves with advanced serology & genetics
• AI-powered disease management tools increase adoption
By 2034, the market is expected to reach USD 10.14 billion, driven by the convergence of therapeutics, diagnostics, and lifestyle-based interventions.
This report is also available in the following languages : Japanese (セリアック病市場), Korean (셀리악병 시장), Chinese (乳糜泻市场), French (Marché de la maladie cœliaque), German (Markt für Zöliakie), and Italian (Mercato della celiachia), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71310
Our More Reports:
Transglutaminase IgA ELISA Test Kit Market
https://exactitudeconsultancy.com/reports/65900/transglutaminase-iga-elisa-test-kit-market
Celiac Disease Testing Market
https://exactitudeconsultancy.com/reports/66017/celiac-disease-testing-market
U.S. Celiac Disease Treatment Market
https://exactitudeconsultancy.com/reports/50330/u-s-celiac-disease-treatment-market
Malabsorption Syndrome Market
https://exactitudeconsultancy.com/reports/51970/malabsorption-syndrome-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Celiac Disease Market is projected to reach USD 10.14 billion by 2034 here
News-ID: 4309875 • Views: …
More Releases from Exactitude Consultancy
Hepatic Impairment Market Registering a CAGR of 4.5%-5.5% during the forecast pe …
Market Overview
The Hepatic Impairment market is growing steadily as the global burden of liver diseases increases, particularly cirrhosis, hepatitis, alcoholic liver disease, and drug-induced liver injury (DILI). Hepatic impairment affects drug metabolism, treatment selection, and patient outcomes, creating substantial demand for specialized diagnostics, monitoring tools, and supportive therapies.
The global hepatic impairment market was valued at USD 14-15 billion in 2024 and is projected to reach USD 20-22 billion by 2032,…
Febrile Neutropenia Market is projected to reach USD 15-17 billion by 2032, regi …
Market Overview
The Febrile Neutropenia market is expanding steadily as global cancer incidence rises and the use of chemotherapy continues to increase. Febrile neutropenia is a potentially life-threatening condition characterized by fever and severely reduced neutrophil counts, most commonly occurring as a complication of cytotoxic cancer treatments.
In 2024, the global Febrile Neutropenia market-driven by prophylactic therapies, antibiotics, diagnostics, and hospital-based management-was valued at USD 10.5-11.5 billion. With the growing adoption of…
Behçet's Disease Market is projected to reach USD 941 million by 2034
The global Behçet's Disease Market was valued at USD 482 million in 2024 and is projected to reach USD 941 million by 2034, expanding at a CAGR of 7.0% during 2025-2034. Growth is driven by increasing disease recognition, rising availability of immunomodulatory therapies, expanding biologics usage for severe manifestations, and improved diagnostic criteria across rheumatology and ophthalmology settings.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71308
Behçet's disease is a…
Rheumatoid Arthritis (RA) Market is Expected to reach USD 95-105 billion by 2032 …
Market Overview
The Rheumatoid Arthritis (RA) market continues to grow steadily as the global burden of autoimmune diseases rises and demand increases for advanced biologic and targeted therapies. RA is a chronic inflammatory autoimmune disorder affecting synovial joints, leading to pain, swelling, progressive disability, and systemic complications if untreated.
The global RA market was valued at USD 65-70 billion in 2024, driven by strong adoption of biologics and JAK inhibitors. With expanding…
More Releases for Celiac
Celiac Disease Market Know the Scope and Trends
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Celiac Disease Market Size, Share & Trends Analysis Report By Treatments (Infliximab, Larazotide Acetate, Gluten Free Diet), Route Of Administration (Oral And Parenteral), End-Users (Hospitals, Homecare), And Distribution Channels (Hospital Pharmacy, Online Pharmacy, And Retail Pharmacy), Region, Market Outlook And Industry Analysis 2031"
The Global Celiac Disease Market is estimated to reach over USD 1,195.5 Mn…
Celiac Disease Market Emerging Trends and Growth Prospects 2034
Introduction
Celiac disease is a chronic autoimmune disorder triggered by gluten ingestion in genetically susceptible individuals, leading to intestinal damage, malabsorption, and systemic complications. Affecting approximately 1% of the global population, the disease remains underdiagnosed, with many patients suffering from undiagnosed or mismanaged symptoms such as abdominal pain, diarrhea, anemia, osteoporosis, and neurological issues.
The cornerstone of treatment for decades has been the lifelong gluten-free diet (GFD), which requires strict avoidance of…
Celiac Disease Market Revenue Report with Forecast to 2031
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Celiac Disease Market Size, Share & Trends Analysis Report By Treatments (Infliximab, Larazotide Acetate, Gluten Free Diet), Route Of Administration (Oral And Parenteral), End-Users (Hospitals, Homecare), And Distribution Channels (Hospital Pharmacy, Online Pharmacy, And Retail Pharmacy), Region, Market Outlook And Industry Analysis 2031"
The Global Celiac Disease Market is estimated to reach over USD 1,195.5 Mn…
Celiac Disease Treatment Market
Celiac disease is an autoimmune disorder that affects the small intestine, triggered by the ingestion of gluten-a protein found in wheat, barley, and rye. This condition leads to inflammation and damage in the intestinal lining, which can hinder nutrient absorption and result in various gastrointestinal and systemic symptoms. As awareness of celiac disease grows, so does the demand for effective treatments and dietary solutions. This post delves into the celiac…
Celiac Disease Drugs Market to Record an Exponential CAGR
Celiac Disease Drugs Market report analyses the prospects in the market for several shareholders and aspirants by identifying the high-growth segments, main actions approved by them and Celiac Disease Drugs market recent progressions. The Celiac Disease Drugs market report is prepared after fundamental levels of research regarding the Celiac Disease Drugs Industry.
Celiac Disease Drugs Market by Drugs (First Line of Treatment and Second Line of Treatment) - Global Opportunity Analysis…
Celiac disease market: Global Trends and Forecast Analysis 2025
Celiac disease is an autoimmune disorder in which the surface of the small intestine is damaged by a protein called gluten. Gluten is found in rye, barley, and wheat. Gluten triggers an immune reaction in the small intestine damaging the villi (small finger-like projections in the small intestine which promote absorption). The damage restricts the ability of the body to absorb proteins, nutrients, fats, vitamins, carbohydrates, and minerals. Eventually, this…
